SLS NASDAQ
SELLAS Life Sciences Group, Inc.
1W: +1.6%
1M: +5.0%
3M: +20.5%
YTD: +179.8%
1Y: +511.6%
3Y: +1173.7%
5Y: +35.5%
$12.17
+0.83 (+7.32%)
Weekly Expected Move ±12.8%
$9
$10
$12
$13
$14
Credit Risk of going bust: lower than 68% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), SELLAS Life Sciences Group, Inc. would be worth roughly what it owes.
Total debt $737K against a stock market value of $2.46B.
Distance to default 7.32 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $658K (short-term plus half of long-term), stock volatility 105.3%; Altman Z'' 16.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), SELLAS Life Sciences Group, Inc. would be worth roughly what it owes.
Total debt $737K against a stock market value of $2.46B.
Distance to default 7.32 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $658K (short-term plus half of long-term), stock volatility 105.3%; Altman Z'' 16.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-03-31
Earliest Filing
2025-10-03
Latest Filing
partner: 2
licensee: 2
Counterparties (Filed by SLS)
4 relationshipsCompanies named in SLS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Times Square Tower Associates LLC | — | partner | Sublandlord in a sublease extension agreement | 2025-10-03 | View |
| Cantor Fitzgerald & Co. | — | partner | Underwriter representing the several underwriters in the public offering of common stock and warrants. | 2022-04-01 | View |
| GenFleet Therapeutics (Shanghai) Inc. | — | licensee | GenFleet granted a sublicensable license for CDK9 inhibitor GFH009 to SELLAS Life Sciences Group, Inc. | 2022-03-31 | View |
| 3D Medicines Inc. | — | licensee | 3D Medicines granted an exclusive license for GPS/GPS+ to SELLAS Life Sciences Group, Inc. | 2022-03-31 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-07-27 | Earnings Release; Other Events; Exhibits | View | |
| 2026-06-25 | Officer/Director Change; Exhibits | View | |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-06-02 | Other Events; Exhibits | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-03-19 | Earnings Release; Exhibits | View | |
| 2026-03-11 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-08 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-27 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-10-03 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-09-11 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-06 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-20 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-29 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-01-23 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR